Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Xiaobing Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4177-5887; OpenAlex author ID A5100375524. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 4

  1. Can astragalus polysaccharides truly boost the treatment of pancreatic cancer? Co-author DOI 10.5306/wjco.v16.i5.101406↗
  2. SMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy. Co-author DOI 10.1038/s41419-024-07210-7↗
  3. A Cyclodiaryliodonium NOX Inhibitor for the Treatment of Pancreatic Cancer via Enzyme-Activatable Targeted Delivery by Sulfated Glycosaminoglycan Derivatives. Co-author DOI 10.1002/adhm.202203011↗
  4. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer. First author DOI 10.1016/j.clinthera.2021.04.012↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Wang · 1 shared paper, 2024 · strength 0.21
  2. Yang Wang · 1 shared paper, 2024 · strength 0.21
  3. Yiran Song · 1 shared paper, 2024 · strength 0.21
  4. Kunxi Bao · 1 shared paper, 2021 · strength 0.19
  5. Lingyan Jian · 1 shared paper, 2021 · strength 0.19
  6. Yang Jiang · 1 shared paper, 2023 · strength 0.17
  7. Shengping Li · 1 shared paper, 2023 · strength 0.17
  8. Jiadong Pang · 1 shared paper, 2023 · strength 0.17
  9. Peng Huang · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.